Locations
Waltham, MA, USA · New York, NY, USA
industry
Biotechnology · DeepTech · Health
Size
11-50 employees
Stage
Other
founded in
2021
Transcend Therapeutics discovers, develops, and delivers the next generation of psychoactive medicine to work towards a world in which people no longer suffer from neuropsychiatric disease. Transcend currently has two lead compounds for depression and fibromyalgia, underserved conditions that disproportionately affect women. Transcend plans to leverage the neuroplastic effects of psychedelic-inspired compounds to treat addiction, pain, anxiety, and other chronic neuropsychiatric conditions with enduring unmet clinical needs. Our leadership team includes the first scientist to receive federal funding for clinical psychedelic research in 54 years and a drug development executive with significant contributions to 9 FDA approvals of New Drug Applications and 5 major M&A deals worth $3.5 billion. As a Public Benefit Corporation, we have pledged 10% of founding shares toward nonprofits focused on scientific research and patient access. We are backed by AlleyCorp, which has launched category defining companies, ranging from databases (MongoDB), eCommerce (Zola), to healthcare (Nomad Health).
Something looks off?© 2023 AlleyCorp. All rights reserved. | Privacy Policy | Terms of Service